Ranking Profile - Atossa Therapeutics Inc

Introduction

Atossa Therapeutics Inc (Atossa), formerly Atossa Genetics Inc is a clinical-stage biopharmaceutical company. It develops proprietary therapeutics and delivery methods for breast cancer and other breast conditions. The company’s pipeline pharmaceutical programs include endoxifen, an active metabolite of tamoxifen, used for the treatment of breast density and other breast health conditions. Atossa is developing patented microcatheter technology to deliver fulvestrant as a potential treatment of ductal carcinoma through the nipple to site of early breast cancer. The company also uses its proprietary intraductal microcatheter technology to deliver CAR-T cells into the ducts of the breast for the treatment of breast cancer. The company has operational presence in Australia, the US and the UK. Atossa is headquartered in Seattle, Washington, the US.